Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial.

[1 ]Oncology Medical Eugene Marquis Comprehensive Cancer Center, Rennes, France;

[2 ]Methodology and Quality of Life Unit, Department of Oncology, INSERM UMR 1098, University Hospital of Besancon; French National Platform Quality of Life and Cancer, Besancon, France;

[3 ]CHU Nord, Saint Etienne, France;

[4 ]CHU Brabois, Vandoeuvre LES Nancy, France;

[5 ]Hopital Beaujon, Clichy, France;

[6 ]Department of Hepatogastroenterology, Amiens University Medical Center, Amiens, France;

[7 ]Centre Paul Strauss, Strasbourg, France;

[8 ]Hopital de la Pitie-Salpétrière, Assistance Publique-Hôpitaux de Paris and Université Pierre et Marie Curie, Sorbonne Universités, Paris, France;

[9 ]Department of Hepato-gastroenterology, University Hospital, Caen, France;

[10 ]University Hospital, Dijon, France;

[11 ]Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, France;

[12 ]Centre Paul Papin, Angers, France;

[13 ]Institut du regional du Cancer de Montpellier (ICM), Montpellier, France;

[14 ]Aix-Marseille University, Assistance Publique Hopitaux de Marseille, Marseille, France;

[15 ]Gustave Roussy Cancer Campus, Villejuif, France;

[16 ]Institut Mutualiste Montsouris, Paris, France;

[17 ]Georges-Francois Leclerc Cancer Center, Dijon, France;

[18 ]UNICANCER, Paris, France;

[19 ]Service d'Oncologie Medicale, Central Eugene Marquis, Rennes, France